{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '(i.e., 3-fold higher than the Phase II dose of 240 mg/day based on dose per m\u00b2', 'body surface area and standard species conversion factors) has resulted in', 'tremors and seizures in dogs, apalutamide is less effective than enzalutamide at', 'crossing the blood-brain barrier. This may result in decreased CNS toxicities in', 'those treated with apalutamide compared to enzalutamide. For instance, while', 'enzalutamide has been implicated in causing seizures in a minority of patients,', 'possibly through off target inhibition of GABA-A, no seizure have occurred in', 'subjects treated on the Phase I/II studies of apalutamide (see apalutamide', \"Investigator's Brochure). 22,37\", 'Individual LNCaPIAR (cs) Xenografts, Oay 28', 'sos', '(castrate males)', '100', '50', 'ARN-509', 'MDV3100', '30 mg/kg', '100 mg/kg', '30 mg/kg', '100 mg/kg', 'O', 'Vehicle', '-50', '13/20', '13/19', '3/19', '12/19', '-100', 'Figure 1: Apalutamide comparative efficacy to enzalutamide (MDV-3100) in', 'mouse xenograft models. Apalutamide is able to achieve maximal therapeutic', 'effect at 30 mg/kg/day compared to 100 mg/kg/day of enzalutamide.', '1.2.1.1. APALUTAMIDE Clinical Trial Experience', 'The first in human Phase I/II study of apalutamide is currently', 'ongoing [Clinicaltrials.gov NCT01171898]. This study is evaluating men', 'with mCRPC. Results from the Phase I portion of this study (N=30)', 'demonstrated that apalutamide is generally safe and well tolerated. At', 'the maximum tested dose of 300 mg daily by mouth only 1/4 subjects', 'experienced a grade 3 adverse event (AE) (abdominal pain). The other', 'three individuals receiving a dose of 300 mg daily did not experience', \"dose limiting toxicities (DLT) (see apalutamide Investigator's Brochure);\", '[Rathkopf, ASCO GU 2012]. Common grade 1-2 AEs observed in the', 'Phase I study included: fatigue (47%), nausea (30%), abdominal pain', '13', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'Pl: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '(20%), arthralgias (13%), diarrhea (17%), dyspnea (13%) and peripheral', 'sensory neuropathy (13%). Five patients experienced serious adverse', 'events and one patient discontinued the study due to an adverse event', '(atrial fibrillation) deemed unrelated to study treatment. PSA declines', '>50% were observed in 12 (55%) patients. 18F-16\u00df-fluoro-5a-', 'dihydrotestosterone (FDHT) PET evaluation demonstrated AR blockade', 'at four weeks across multiple doses. Given promising activity observed', 'across all doses in conjunction with no appreciable difference in FDHT-', 'PET uptake at 240 mg compared to 300 mg of apalutamide, a dose of', '240 mg has been selected for Phase II testing.22,24', 'The Phase II portion of this study is ongoing and will evaluate', 'three expansion cohorts with a total enrollment of 97 patients ( see', \"apalutamide Investigator's Brochure). 22 The primary endpoint of the\", 'Phase Il study is PSA response at 12 weeks according to Prostate', 'Cancer Working Group 2 (PCWG2) Criteria. All cohorts will consist of', 'men who are chemotherapy na\u00efve and have CRPC. Specific cohorts are:', '1) non-metastatic CRPC, 2) mCRPC pre-abiraterone acetate and 3)', 'mCRPC post-abiraterone acetate. Preliminary results for the non-', 'metastatic CRPC cohort, mCRPC pre-abiraterone acetate cohort and the', 'mCRPC post-abiraterone acetate cohort demonstrated >50% PSA', 'declines at 12-weeks in 91% (41/45), 88% (22/25) and 29% (4/14)', \"subjects, respectively (see apalutamide Investigator's Brochure). 38 The\", 'most frequent, treatment-emergent, all causality, adverse events', 'observed in > 10% of patients were fatigue (43%), diarrhea (32%),', 'abdominal pain (25%), and nausea (23%). Table 6 in the apalutamide', \"Investigator's Brochure lists all Phase II AEs reported in more than 3\", 'patients by cohort. In Phase II, as of 20 August 2012, there were three', 'Grade 3 treatment-related AEs: diarrhea, abdominal pain, and rash. Both', 'diarrhea and rash occurred in NM-CRPC patients, with start dates', 'approximately one month after the start of treatment and both were', 'ongoing at the time of the data cut. The third Grade 3 AE (abdominal', 'pain) occurred in a metastatic treatment-na\u00efve CRPC patient, starting 29', 'days after the start of treatment. It resolved after eight days of study', '14', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}